Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7820721 | 0.82 | GPR174 (0.75) | GPR174GAAALDH1A1RECQLMEN1 | |
| SCHEMBL30545905 | 0.82 | GPR174 (0.75) | GPR174GAAALDH1A1RECQLMEN1 | |
| SCHEMBL10046487 | 0.81 | GAA (0.73) | GAAALDH1A1ALOX15MEN1KMT2A | |
| SCHEMBL10046494 | 0.79 | GAA (0.56) | GAAALDH1A1MEN1KMT2APOLB | |
| SCHEMBL10046493 | 0.79 | GAA (0.47) | GPR174GAAALDH1A1MEN1KMT2A | |
| SCHEMBL10046482 | 0.78 | GAA (0.51) | GPR174GAAALDH1A1MEN1KMT2A | |
| SCHEMBL10046492 | 0.77 | GAA (0.46) | GAAALDH1A1MEN1KMT2APOLB | |
| SCHEMBL24337097 | 0.77 | ALDH1A1 (0.67) | GAAALDH1A1RECQLALOX15MEN1 | |
| SCHEMBL14904060 | 0.74 | GAA (0.51) | GAAALDH1A1MEN1KMT2APOLB | |
| SCHEMBL22388482 | 0.73 | GPR174 (1.00) | GPR174GAAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906416-B2 | Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2014-12-09 | — | — | US | disclosed |
| US-8906416-B2 | Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2014-12-09 | — | — | US | disclosed |
| EP-2590959-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | Pierre Fabre Dermo-Cosmétique (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-20130108568-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2013-05-02 | — | — | US | disclosed |
| US-20130108568-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2013-05-02 | — | — | US | disclosed |
| US-20130108568-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004390-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004390-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130108568-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | ACOX3, CBR3, GALR3 | GPR174 2126/4885GAA 1289/4885ALDH1A1 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.